Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Micurx Pharmeceuticals Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This prosecution involves 1 distinct examiner and 1 distinct art unit, indicating a focused examination process for the company's pharmaceutical filings. This centralized prosecution means that the immediate progress of the company's intellectual property depends on the review of the examiner.
The busiest examiner for the portfolio is GAUGER, PAUL RANDALL. This examiner is responsible for 1 busiest examiner pending action, which matches the total count of 1 pending office action for the company. With only the distinct art unit involved, the company's current patent strategy is dependent on the outcomes within that group. Practitioners should note that this lack of diversification across examiners means the specific examination style of the individual will determine the progress of the active application at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GAUGER, PAUL RANDALL | 1 | 59.3% | +8.3% |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18605432 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | GAUGER, PAUL RANDALL | 1629 | DP | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMicurx Pharmeceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Randall Gauger has the most, with 1 of Micurx Pharmeceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
